Monopar Therapeutics logo

Monopar Therapeutics Share Price Today

(NASDAQ: MNPR)

Monopar Therapeutics share price is $30.8 & ₹2,678.65 as on 6 Mar 2025, 2.30 'hrs' IST

$30.8

-0.9

(-2.84%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Monopar Therapeutics share price in Dollar and Rupees. Guide to invest in Monopar Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Monopar Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Monopar Therapeutics share price movements

  • Today's Low: $29.26
    Today's High: $32.20

    Day's Volatility :9.14%

  • 52 Weeks Low: $1.72
    52 Weeks High: $54.30

    52 Weeks Volatility :96.83%

Monopar Therapeutics (MNPR) Returns

PeriodMonopar Therapeutics IncIndex (Russel 2000)
3 Months
50.95%
0.0%
6 Months
1204.53%
0.0%
1 Year
560.42%
0.0%
3 Years
104.85%
-11.6%

Monopar Therapeutics (MNPR) Key Statistics

in dollars & INR

Previous Close
$31.7
Open
$31.75
Today's High
$32.2
Today's Low
$29.2555
Market Capitalization
$193.8M
Today's Volume
$3.8K
52 Week High
$54.3
52 Week Low
$1.719
Revenue TTM
$0.0
Earnings Per Share (EPS)
$-1.93
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-112.04%

How to invest in Monopar Therapeutics Stock (MNPR) from India?

It is very easy for Indian residents to invest directly in Monopar Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Monopar Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Monopar Therapeutics or MNPR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Monopar Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Monopar Therapeutics shares which would translate to 0.028 fractional shares of Monopar Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Monopar Therapeutics, in just a few clicks!

Returns in Monopar Therapeutics (MNPR) for Indian investors in Rupees

The Monopar Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Monopar Therapeutics investment value today

Current value as on today

₹6,46,629

Returns

₹5,46,629

(+546.63%)

Returns from Monopar Therapeutics Stock

₹5,41,667 (+541.67%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Monopar Therapeutics (MNPR)

-22%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Monopar Therapeutics Stock from India on INDmoney has decreased by -22% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Monopar Therapeutics

  • HHG PLC

    17.16%

  • Adage Capital Partners Gp LLC

    9.82%

  • RA Capital Management, LLC

    8.38%

  • Point72 Asset Management, L.P.

    2.75%

  • ADAR1 Capital Management LLC

    2.13%

  • Vanguard Group Inc

    0.93%

Analyst Recommendation on Monopar Therapeutics

Buy

    87%Buy

    12%Hold

    0%Sell

Based on 8 Wall street analysts offering stock ratings for Monopar Therapeutics(by analysts ranked 0 to 5 stars)

Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
6
7
Hold
1
2
3
Sell
0
0
0

Analyst Forecast on Monopar Therapeutics Stock (MNPR)

What analysts predicted

Upside of 69.64%

Target:

$52.25

Current:

$30.80

Insights on Monopar Therapeutics Stock (Ticker Symbol: MNPR)

  • Price Movement

    In the last 6 months, MNPR stock has moved up by 1204.5%

Monopar Therapeutics Technicals Summary

Sell

Neutral

Buy

Monopar Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Monopar Therapeutics (MNPR) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Monopar Therapeutics Inc logo
-27.21%
1204.53%
560.42%
104.85%
-25.41%
Regeneron Pharmaceuticals, Inc. logo
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Monopar Therapeutics Inc logo
NA
NA
NA
-1.77
-1.12
-0.6
NA
1.4
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Monopar Therapeutics Inc logo
Buy
$193.8M
-25.41%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Monopar Therapeutics

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
Organization
Monopar Therapeutics
Employees
9
CEO
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Industry
Health Technology

Management People of Monopar Therapeutics

NameTitle
Dr. Christopher M. Starr Ph.D.
Co-Founder & Independent Executive Chairman of the Board
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Co-Founder, CEO, President & Director
Mr. Andrew J. Cittadine M.B.A.
Chief Operating Officer
Mr. Karthik Radhakrishnan CFA
CFO, Principal Accounting Officer & Principal Financial Officer
Dr. Patrice P. Rioux M.D., Ph.D.
Acting Chief Medical Officer

Important FAQs about investing in MNPR Stock from India :

What is Monopar Therapeutics share price today?

Monopar Therapeutics share price today stands at $30.80, Open: $31.75 ; Previous Close: $31.70 ; High: $32.20 ; Low: $29.26 ; 52 Week High: $54.30 ; 52 Week Low: $1.72.

The stock opens at $31.75, after a previous close of $31.70. The stock reached a daily high of $32.20 and a low of $29.26, with a 52-week high of $54.30 and a 52-week low of $1.72.

Can Indians buy Monopar Therapeutics shares?

Yes, Indians can invest in the Monopar Therapeutics (MNPR) from India.

With INDmoney, you can buy Monopar Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Monopar Therapeutics at zero transaction cost.

How can I buy Monopar Therapeutics shares from India?

It is very easy to buy Monopar Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Monopar Therapeutics (MNPR) be purchased?

Yes, you can buy fractional shares of Monopar Therapeutics with INDmoney app.

What are the documents required to start investing in Monopar Therapeutics stocks?

To start investing in Monopar Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Monopar Therapeutics Stock (MNPR)?

Today’s highest price of Monopar Therapeutics (MNPR) is $32.20.

Today’s lowest price of Monopar Therapeutics (MNPR) is $29.26.

What is today's market capitalisation of Monopar Therapeutics?

Today's market capitalisation of Monopar Therapeutics MNPR is 193.8M

What is the 52 Week High and Low Range of Monopar Therapeutics Stock (MNPR)?

  • 52 Week High

    $54.30

  • 52 Week Low

    $1.72

What are the historical returns of Monopar Therapeutics (MNPR)?

  • 1 Month Returns

    -27.21%

  • 3 Months Returns

    1204.53%

  • 1 Year Returns

    560.42%

  • 5 Years Returns

    -25.41%

Who is the Chief Executive Officer (CEO) of Monopar Therapeutics ?

Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc is the current Chief Executive Officer (CEO) of Monopar Therapeutics.